ArticleEndocrine2026
Association of the triglyceride glucose-Chinese visceral adiposity index with incident sarcopenia among middle-aged and older adults with diabetes: a prospective cohort study.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLongitudinal association of triglyceride glucose-Chinese visceral adiposity index (TyG-CVAI) with the risk of new-onset sarcopenia in middle-aged and older adults with diabetes remains unclear. This study aimed to investigate whether baseline and cumulative TyG-CVAI is associated with incident sarcopenia risk in middle-aged and older adults with diabetes.
methodsWe included participants aged ≥ 50 years with diabetes from the China Health and Retirement Longitudinal Study (CHARLS) 2011-2012. TyG-CVAI was calculated as TyG index multiplied by CVAI. Multivariable Cox regression and logistic regression were used to examine the associations of baseline and cumulative TyG-CVAI with new-onset sarcopenia. Receiver operating characteristic (ROC) curves were employed to compare the predictive capability of TyG-CVAI with its individual components.
resultsA total of 763 participants with diabetes were included in the baseline analysis. During the 4-year follow-up, 62 (8.1%) participants developed new-onset sarcopenia. Compared with the lowest quartile (Q1) of baseline TyG-CVAI, the highest quartile (Q4) was significantly associated with an increased risk of sarcopenia (HR = 2.368, 95% CI: 1.014-5.532) in the fully adjusted model, with a significant trend across quartiles (P for trend = 0.017). Compared with the low-stable group (Cluster 1, n = 198), the high-stable group (Cluster 2, n = 276) had a significantly higher risk of new-onset sarcopenia (OR = 1.100, 95% CI: 1.020-1.321). The predictive performance of baseline TyG-CVAI (AUC = 0.685, 95% CI: 0.611-0.747) and cumulative TyG-CVAI (AUC = 0.917, 95% CI: 0.845-0.962) was higher than that of baseline and cumulative TyG and CVAI.
conclusionElevated baseline and cumulative TyG-CVAI are associated with new-onset sarcopenia in middle-aged and older Chinese adults with diabetes.
Indexed as
Identifiers
42545547What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.